Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR: Psilocybin Dose-Response and 5-HT2A Role
NCT06796361Phase 1Recruiting
- Sponsor
- University Hospital Basel
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in anxiety disorder, major depressive disorder (MDD), substance use disorder (SUD) and 1 more (6 arms), sponsored by University Hospital Basel. Primary endpoint: 5 Dimensions of Altered State of Consciousness Total OAV Score. Started Apr 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)substance use disorder (SUD)personality disorders
Beyond the preview
Go deeper on NCT06796361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796361.